Complete Guide to Pediatric Asthma Medications and Biologics
A comprehensive StatPearls review covering every drug class used to treat childhood asthma, from inhalers to cutting-edge biologics.
Summary
Asthma affects roughly 14% of children worldwide, making it the most common chronic respiratory disease of childhood. This StatPearls reference article reviews the full spectrum of pediatric asthma treatments, including short- and long-acting bronchodilators, inhaled and systemic corticosteroids, leukotriene receptor antagonists, mast cell stabilizers, and methylxanthines. It also covers newer biologic therapies such as omalizumab, mepolizumab, benralizumab, and dupilumab, which target specific inflammatory pathways like IgE, IL-5, and IL-4/IL-13 signaling. Diagnosis in children is more challenging than in adults because spirometry is unreliable in young patients, so clinicians rely on clinical history, trigger patterns, FeNO testing, and response to controller therapy. Management follows NAEPPCC, NHLBI, and GINA guidelines.
Detailed Summary
Asthma is the leading chronic respiratory condition in children, affecting approximately 14% of pediatric patients globally. Unlike adults, children cannot reliably perform spirometry, making diagnosis dependent on clinical history, symptom patterns, family history, FeNO testing, and observed response to bronchodilator therapy. This complexity makes evidence-based pharmacological guidance especially important for clinicians managing young patients.
This StatPearls reference chapter systematically reviews every major drug class used in pediatric asthma management. Quick-relief medications include short-acting beta-2 agonists such as albuterol and levalbuterol, which rapidly reverse bronchoconstriction. Controller therapies include inhaled corticosteroids like budesonide and fluticasone, which suppress airway inflammation and prevent remodeling, as well as long-acting beta-2 agonists, long-acting muscarinic antagonists like tiotropium, and leukotriene receptor antagonists such as montelukast.
The article gives notable attention to biologic therapies that have transformed severe pediatric asthma management. Omalizumab targets IgE to prevent mast cell degranulation. Mepolizumab and benralizumab reduce eosinophilic inflammation via IL-5 pathway blockade. Dupilumab inhibits IL-4 and IL-13 signaling, addressing type 2 inflammatory mechanisms. Subcutaneous immunotherapy is also reviewed as a disease-modifying option for allergen-sensitized patients.
For clinicians, the practical value lies in understanding which drug class to deploy at each severity level and age group, and when to escalate to biologics. The GINA guideline update endorsing ICS-formoterol as both controller and reliever therapy is highlighted as a significant management shift.
Limitations include the article's format as a narrative reference chapter rather than a systematic review or meta-analysis, meaning it synthesizes existing guidelines rather than generating new evidence. The summary here is based solely on the abstract, and the full clinical detail within the chapter was not accessible for review.
Key Findings
- Approximately 14% of children worldwide have asthma, the most common chronic respiratory disease of childhood.
- Spirometry is unreliable in young children; diagnosis relies on clinical history, FeNO testing, and bronchodilator response.
- ICS-formoterol is now endorsed by GINA as both controller and quick-relief therapy, a significant guideline shift.
- Biologics targeting IgE, IL-5, and IL-4/IL-13 pathways offer new options for severe, refractory pediatric asthma.
- Subcutaneous immunotherapy remains a viable disease-modifying option for allergen-sensitized pediatric patients.
Methodology
This is a narrative reference chapter published in StatPearls, a continuously updated medical education resource. It synthesizes current NAEPPCC, NHLBI, and GINA guidelines rather than conducting original research or systematic literature searches with defined inclusion criteria. No primary data collection or statistical analysis was performed.
Study Limitations
This summary is based on the abstract only, as the full text was not accessible; detailed clinical recommendations within the chapter could not be reviewed. The article is a narrative educational reference, not a systematic review or meta-analysis, so it does not provide pooled effect sizes or formal evidence grading. Guideline recommendations may not reflect the most recent updates published after the chapter's last revision date.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.